CHRNA7 and schizophrenia: Previously, α7 nAChR agonists have been tested for the treatment of schizophrenia, but failed in phase 3 clinical trials because of unwanted side effects (Tregellas et al., 2011; Tregellas and Wylie, 2019), and rapid receptor desensitization (Gulsevin et al., 2019).